Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:16:49.633Z.
Calculation as of: 2026-10-06T16:16:49.633Z.
Quote observation: 2026-10-06T16:15:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2e4786eb28a8a31d15cdec8f673983fbe0ec0b626c310469f8e20e074e44c13d
PE RATIO
N/A
Market Cap
$718.54M
PE Ratio
17.87
TTM Avg
23.33
3Y Avg
39.10
5Y Avg
32.90
Market Cap
$717.52M
PE Ratio
N/A
TTM Avg
359.25
3Y Avg
359.25
5Y Avg
359.25
Market Cap
$771.14M
PE Ratio
164.05
TTM Avg
129.79
3Y Avg
309.15
5Y Avg
358.87
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | $737.29M | N/A | N/A | N/A | N/A |
| Achieve Life Sciences, Inc. (ACHV)vs › | $737.09M | N/A | N/A | N/A | N/A |
| Candel Therapeutics, Inc. (CADL)vs › | $744.43M | N/A | N/A | N/A | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $720.01M | N/A | 991.02 | 502.52 | 502.52 |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $718.54M | 17.87 | 23.33 | 39.10 | 32.90 |
| Avalo Therapeutics, Inc. (AVTX)vs › | $717.52M | N/A | 359.25 | 359.25 | 359.25 |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $713.86M | N/A | N/A | N/A | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $763.85M | N/A | N/A | N/A | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $771.14M | 164.05 | 129.79 | 309.15 | 358.87 |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $779.56M | N/A | 12.44 | 5.97 | 5.97 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$28.60
Forward EPS (Est.)
$-15.07
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
